phenyl N-[4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl]carbamate

We are phenyl N-[4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl]carbamate CAS:184177-81-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: phenyl N-[4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl]carbamate
CAS.NO: 184177-81-9
Synonyms:
4-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-phenyl-carbamic acid phenyl ester
phenyl {4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl}carbamate
phenyl {4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl}carbamate

Molecular Formula:C23H23N3O3
Molecular Weight:389.44700

Physical and Chemical Properties:
Density: 1.296g/cm3
Boiling point: 603.9ºC at 760 mmHg
Melting point: /
Flash point: 319ºC
Refractive index: 1.67

Specification:
Appearance: White or off-white powder
Purity:≥99%
Water:≤0.5%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Posaconazole CAS:171228-49-2

phenyl N-[4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl]carbamate


Related News: Pharmaceutical intermediates and APIs belong to the fine chemical industry.2,4-Bis(phenylsulfonyl)phenol A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018.2-(Trifluoromethoxy)aniline CAS:1535-75-7 A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018.(3S,4R)-4-Acetoxy-3-[(R)-1-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-one In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.

Related Products
Product Name
2-(4-bromo-phenyl)-1(9)H-benzo[d]imidazo[1,2-a]imidazole View Details
4-Fluoroanisole View Details
5-Chloro-2-fluorobenzoic acid View Details
Dimethyl trisulfide manufacturer 2-Methoxy-4-nitroaniline manufacturer 2-Bromopropionyl bromide manufacturer 2-Methoxy-5-Nitro-6-Picoline manufacturer (10-(Naphthalen-1-yl)anthracen-9-yl)boronic acid manufacturer